The Quantellect read.As of Nov 19, 2026, 6 active firms cover NewAmsterdam Pharma Company N.V. Ordinary Shares: 5 rate it Buy or better, 1 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets are tightly clustered, $42.00 to $52.00, so the covering firms are broadly aligned. The average target of $46.75 sits 137% above the current $19.76. The rating mix has stayed broadly stable, with Buy-side ratings easing from 6 to 5 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.49 next quarter toward $-1.90 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS6 active firms
Buy
Strong Buy00%
Buy583%
Neutral117%
Sell00%
Strong Sell00%
Based on 6 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$46.75
+136.6% upside
Average target across 4 active firms as of Nov 19, 2026 vs $19.76 current
Highest Target$52.00
Average Target$46.75
Lowest Target$42.00
Detailed analyst forecasts for NAMS
Showing 1–4 of 4 named analysts shown · 6 active firms in the rating projection
As of Nov 19, 2026, 5 of 6 active firms rate NAMS a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
NAMS EPS & revenue forecast
EPS · NEXT QUARTER
$-0.49
Range $-0.54 – $-0.45 · 5 analysts · +44% YoY
Next period, 5 analysts expect NewAmsterdam Pharma Company N.V. Ordinary Shares to earn $-0.49 a share (range $-0.54 – $-0.45), versus $-0.34 a year earlier. Full-year consensus is $-1.33, growing to $-1.90 the year after.
REVENUE · NEXT QUARTER
$1.2M
Range $0 – $4.9M · 5 analysts · -52% YoY
Revenue is expected to reach $1.2M (range $0 – $4.9M), -52.2% year-over-year. Full-year consensus is $34.9M, rising to $43.0M next year.
Top analysts covering NewAmsterdam Pharma Company N.V. Ordinary Shares
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on NAMS.
#1
Leonid Timashev
RBC Capital · Rank #27
Buy
$42.00+112.6% to target
Overall win rate
52%
+ Follow
#2
Serge Belanger
Needham · Rank #129
Buy
$48.00+142.9% to target
Overall win rate
46%
+ Follow
#3
Debjit Chattopadhyay
Guggenheim · Rank #248
Buy
$45.00+127.7% to target
Overall win rate
39%
+ Follow
#4
George Farmer
Scotiabank · Rank #311
Buy
$52.00+163.2% to target
Overall win rate
44%
+ Follow
#5
Yasmeen Rahimi
Piper Sandler · Rank #339
Buy
$60.00+203.6% to target
Overall win rate
30%
+ Follow
NAMS stock forecast FAQ
What is NAMS's average 12-month price target?+
The 4 active firms with a live target average $46.75 for NewAmsterdam Pharma Company N.V. Ordinary Shares over the next 12 months, ranging from a $52.00 high to a $42.00 low, as of Nov 19, 2026.
Is NAMS stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 6 active firms as of Nov 19, 2026, 5 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for NAMS?+
The Street-high target is $52.00 (HC Wainwright & Co.), and the Street-low is $42.00 (RBC Capital). The average of all 4 active-firm targets is $46.75.
How many active Wall Street firms cover NAMS?+
6 active firms have a recognized rating on NewAmsterdam Pharma Company N.V. Ordinary Shares as of Nov 19, 2026, and 4 active firms carry a live 12-month price target.
Who is the most accurate analyst covering NAMS?+
Among analysts who currently cover NAMS, Leonid Timashev of RBC Capital has the strongest overall Quantellect track record (Rank #27). Their current call is Buy with a $42.00 target.
What is NewAmsterdam Pharma Company N.V. Ordinary Shares's projected EPS for next quarter?+
The consensus estimate is $-0.49 per share (range $-0.54 – $-0.45) across 5 analysts. Full-year EPS is projected at $-1.33, rising to $-1.90 the following year.
How much revenue is NewAmsterdam Pharma Company N.V. Ordinary Shares expected to report next quarter?+
Consensus revenue is $1.2M (range $0 – $4.9M). Full-year revenue is projected at $34.9M, growing to $43.0M next year.
Have analysts been upgrading or downgrading NAMS lately?+
As of Nov 19, 2026, 5 of 6 active firms rate NAMS a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their NAMS calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.